Alopecia areata - Journal of the American Academy of Dermatology
网页Alopecia areata (AA) is a common, inflammatory, nonscarring type of hair loss. Significant variations in the clinical presentation of AA have been observed, ranging from small, well-circumscribed patches of hair loss to a complete absence of body and scalp hair.
Alopecia Areata | Dermatology - JAMA Network
网页Alopecia Areata (AA) is a type of hair loss disorder caused by the immune system. It most often appears as patchy areas of hair loss on the scalp but can occur anywhere on the body. AA can affect people of any age, race, or sex. While not a dangerous condition, it can substantially affect patients’ lives. Hair loss in AA can be unpredictable.
Journal of the European Academy of Dermatology and Venereology
网页2024年1月2日 · When using the AAS, moderate to severe alopecia areata should be considered a medical indication for systemic treatment. Currently, the only two EMA-approved medications for alopecia areata are baricitinib (JAK 1/2 inhibitor) for adults and ritlecitinib (JAK 3/TEC inhibitor) for individuals aged 12 and older.
Alopecia areata - Journal of the American Academy of Dermatology
网页Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial J Dermatolog Treat. 2005; 16 :10-14
British Association of Dermatologists’ guidelines for the …
网页2012年5月1日 · Alopecia areata is a chronic inflammatory disease that affects the hair follicle and sometimes the nail. The onset may be at any age and there is no known race or sex preponderance. Alopecia areata usually presents as patches of hair loss on the scalp but any hair‐bearing skin can be involved.
The Alopecia Areata Consensus of Experts (ACE) study: Results of …
网页This is the first international consensus document to comprehensively address expert assessment of treatment of alopecia areata. An international patient registry for alopecia areata is proposed to enable research to address areas where consensus is currently lacking and data are limited.
European expert consensus statement on the systemic treatment …
网页2024年1月4日 · Currently, the only two EMA-approved medications for alopecia areata are baricitinib (JAK 1/2 inhibitor) for adults and ritlecitinib (JAK 3/TEC inhibitor) for individuals aged 12 and older. Both are EMA-approved for patients with severe alopecia areata.
A Practical Approach to the Treatment of Alopecia Areata
网页2022年10月31日 · Alopecia areata (AA) is an autoimmune condition characterized by non-scarring patchy alopecia. It may present as circumscribed patchy alopecia or diffuse hair loss and sometimes may progress to involve the entire scalp or body.
Alopecia areata – Current understanding and management
网页Alopecia areata (AA) is a chronic, immune-mediated disease characterized by acute onset of non-scarring hair loss ranging from small circumscribed patchy areas on the scalp, to complete scalp and body hair loss. Until recently our understanding of the pathophysiology of AA was only scarce, despite being so common, affecting both children and ...
Alopecia areata: Recent advances and emerging therapies
网页Alopecia areata is an acquired, chronic, non-scarring hair disorder of the skin affecting 0.5-2% of the general population worldwide. Multiple mechanisms are involved in the disease, namely genetic predisposition, environmental triggers, impaired hair growth, and altered inflammatory and immune responses.